slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 74,191-74,220
Pages 3,679
Rows per page 30
Component
74,191-74,220 of 110,355
13
The slide uses two charts to argue that traditional active management is failing to provide alpha, justifying a shift toward alternative strategies.Apollo Global Management | Investor Presentation Deck | 42 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
16
The slide uses a stacked bar chart to visualize the transition from traditional 60/40-style allocations to a more diversified structure including private credit and hybrid equity.Apollo Global Management | Investor Presentation Deck | 42 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
18
Uses a visual comparison of two circles to illustrate market expansion potential.Apollo Global Management | Investor Presentation Deck | 42 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
20
The slide uses a process-like diagram to show how Apollo/Athene and 3rd-party investors converge on specific investment vehicles.Apollo Global Management | Investor Presentation Deck | 42 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
23
Reflects targets previously communicated at Apollo's Investor Day in October 2021.Apollo Global Management | Investor Presentation Deck | 42 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
04
The slide uses a column-based layout with icons and supporting text to present company strengths.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent clinical trial progress.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to diagnosed to treated.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a process-flow diagram to show how different mechanisms of action (NA, RNAi, PD-L1 Inhibitor, Interferon, Vaccines) contribute to the three pillars of the therapeutic approach.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The slide outlines trial design cohorts (E, F, G, I, J, K) and summarizes findings from parts 1 & 2.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The table displays mean (SE) log10 IU/mL values for various cohorts (E, F, I, J, K, G) from baseline through follow-up week 48.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
The slide displays 8 individual patient charts tracking biomarker levels over time, with specific annotations for NA retreatment.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
16
The slide uses a bulleted list format to present key safety findings.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
17
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
18
The slide uses a timeline-based process diagram to illustrate the randomization and treatment arms of the clinical trial.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
22
The slide uses a three-column layout to explain the scientific basis and therapeutic advantages of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
23
The slide shows two distinct experiments: an in vitro T-cell activation assay and an in vivo tumor reduction study.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
25
The slide uses checkmarks to indicate completed milestones.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · Financials1 hit
06
The slide uses a hub-and-spoke visual arrangement around a central patient image.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a chronological progression (Today vs Future) to outline product development strategy.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
14
The slide outlines a clinical trial protocol timeline.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
15
The slide outlines a clinical trial protocol with a 1-3 week screening phase followed by a 30-week treatment period.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
04
The chart shows the progression from revenue components to gross profit, operating income, and free cash flow.arm | Investor Presentation Deck | 8 slides · Arm
Conference presentation Investor relations 1 hit
06
The chart combines absolute revenue (bars) with percentage growth (line).arm | Investor Presentation Deck | 8 slides · Arm
Conference presentation Investor relations 1 hit
03
The slide uses a visual arrow diagram to contrast H1 headwinds with H2 profit/cash generation.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Situation & Context1 hit
08
The slide highlights improvements in margins and specific cost categories (Distribution, Warehouse, Other) following H1 initiatives.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Problem & Complication1 hit
11
The slide highlights the negative impact of reduced stock intake on cash flow.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations 1 hit
14
The slide uses a three-stage horizontal progression to outline strategic financial priorities.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Solution & Approach1 hit